Patient selection is crucial for vaccine therapy success in kidney cancer
Robert Figlin, MD, of Cedars-Sinai Medical Center, Los Angeles, CA, gives an update on the ADAPT trial (NCT01582672), which investigates autologous dendritic cell vaccine therapy plus the standard of ...
Author: VJOncology
Added: 08/22/2018
Source: Oncology Tube - Category: Cancer & Oncology Source Type: podcasts
More News: Cancer | Cancer & Oncology | Cancer Vaccines | Kidney Cancer | Urology & Nephrology | Vaccines